Literature DB >> 377080

Somatostatinoma syndrome. Biochemical, morphologic and clinical features.

G J Krejs, L Orci, J M Conlon, M Ravazzola, G R Davis, P Raskin, S M Collins, D M McCarthy, D Baetens, A Rubenstein, T A Aldor, R H Unger.   

Abstract

Diabetes mellitus, steatorrhea, cholelithiasis and a tumor distorting the duodenum prompted a work-up for somatostatinoma in a 52-year-old man. The responses of pancreatic B-cells but not of A-cells to nutrient stimuli were inhibited, and growth-hormone release was suppressed, suggesting somatostatin resistance in some target tissues. Plasma somatostatin-like immunoreactivity ranged from 9000 to 13,000 pg per milliliter (normal: 88+/-8, mean +/- S.E.M.) and was distributed in four molecular forms, including free somatostatin. The primary tumor contained 5 microgram of somatostatin-like immunoreactivity per milligram of wet tissue, distributed in three of the molecular forms noted in plasma. Plasma calcitonin was also elevated (4650 pg per milliliter; normal: less than 120). Immunocytochemical studies showed that cells of the primary tumor contained somatostatin and calcitonin but no other peptide hormones. Only somatostatin was present in the metastases. Somatostatin was localized electron microscopically in all secretory granules, irrespective of size and shape, whereas calcitonin was present only within a single subpopulation of small granules in the same cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 377080     DOI: 10.1056/NEJM197908093010601

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  59 in total

1.  Co-secretion of calcitonin gene-related peptide, gastrin-releasing peptide and ACTH by a carcinoid tumour metastasizing to the cerebellum.

Authors:  M A Ghatei; M R Stratton; J M Allen; G F Joplin; J M Polak; S R Bloom
Journal:  Postgrad Med J       Date:  1987-02       Impact factor: 2.401

2.  [Tumors of the endocrine pancreas].

Authors:  M Anlauf; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2005-02       Impact factor: 1.011

3.  Effect of octreotide on human sphincter of Oddi motility following liver transplantation.

Authors:  F H Weber; R J Sears; B Kendall; T L Pruett; H A Shaffer; P Yeaton
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

4.  Plasma gut hormone levels in 37 patients with pheochromocytomas.

Authors:  A I Vinik; B Shapiro; N W Thompson
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

Review 5.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 6.  [Tumors of the endocrine pancreas].

Authors:  G Klöppel
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

7.  Duodenal and ampullary carcinoid tumors. A report of 12 cases with pathological characteristics, polypeptide content and relation to the MEN I syndrome and von Recklinghausen's disease (neurofibromatosis).

Authors:  B Stamm; C E Hedinger; P Saremaslani
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

Review 8.  Morphological and functional investigations of neuroendocrine tumors of the pancreas.

Authors:  Philippe L Pereira; Jakub Wiskirchen
Journal:  Eur Radiol       Date:  2003-05-06       Impact factor: 5.315

9.  Human somatostatin I: sequence of the cDNA.

Authors:  L P Shen; R L Pictet; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

10.  Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes.

Authors:  D Grama; B Eriksson; H Mårtensson; B Cedermark; B Ahrén; A Kristoffersson; J Rastad; K Oberg; G Akerström
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.